ECSP11011149A - Agonistas del receptor gpr120 y usos de los mismos - Google Patents
Agonistas del receptor gpr120 y usos de los mismosInfo
- Publication number
- ECSP11011149A ECSP11011149A EC2011011149A ECSP11011149A ECSP11011149A EC SP11011149 A ECSP11011149 A EC SP11011149A EC 2011011149 A EC2011011149 A EC 2011011149A EC SP11011149 A ECSP11011149 A EC SP11011149A EC SP11011149 A ECSP11011149 A EC SP11011149A
- Authority
- EC
- Ecuador
- Prior art keywords
- gpr120
- same
- agonists
- receiver agonists
- receiver
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Secondary Cells (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Abstract
Se proveen agonistas de GPR120. Estos compuestos son útiles para el tratamiento de enfermedades metabólicas, incluyendo diabetes tipo II y enfermedades asociadas con escaso control glicémico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13892308P | 2008-12-18 | 2008-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011149A true ECSP11011149A (es) | 2011-08-31 |
Family
ID=41818563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011149A ECSP11011149A (es) | 2008-12-18 | 2011-06-17 | Agonistas del receptor gpr120 y usos de los mismos |
Country Status (27)
Country | Link |
---|---|
US (3) | US8309600B2 (es) |
EP (2) | EP2514745A1 (es) |
JP (1) | JP5746975B2 (es) |
KR (1) | KR20110096071A (es) |
CN (2) | CN103980235A (es) |
AR (1) | AR074760A1 (es) |
AU (1) | AU2009335797A1 (es) |
BR (1) | BRPI0922483A2 (es) |
CA (1) | CA2746762A1 (es) |
CL (1) | CL2011001497A1 (es) |
CO (1) | CO6400136A2 (es) |
CR (1) | CR20110344A (es) |
DK (1) | DK2367793T3 (es) |
EA (1) | EA021515B1 (es) |
EC (1) | ECSP11011149A (es) |
ES (1) | ES2416980T3 (es) |
HK (1) | HK1162023A1 (es) |
IL (1) | IL213569A0 (es) |
MX (1) | MX2011006574A (es) |
NI (1) | NI201100126A (es) |
NZ (2) | NZ611429A (es) |
SG (2) | SG196838A1 (es) |
SV (1) | SV2011003954A (es) |
TW (1) | TW201028389A (es) |
UA (1) | UA105779C2 (es) |
WO (1) | WO2010080537A1 (es) |
ZA (1) | ZA201104570B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2300442A2 (en) * | 2008-06-24 | 2011-03-30 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
JP2012506386A (ja) * | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
DK2582674T3 (en) * | 2010-06-16 | 2014-12-15 | Cymabay Therapeutics Inc | GPR120 receptor agonists and uses thereof. |
US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
CN103080769A (zh) | 2010-09-14 | 2013-05-01 | 松下电器产业株式会社 | 雷达装置 |
GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
PT2694116T (pt) | 2011-04-06 | 2018-10-12 | Univ Texas | Nanopartículas à base de lípidos |
EP2758041B1 (de) | 2011-09-20 | 2021-01-13 | Basf Se | Niedermolekulare modulatoren des kälte-menthol-rezeptors trpm8 und deren verwendung |
AU2012365706B2 (en) | 2012-01-12 | 2015-08-20 | Jiangsu Hengrui Medicine Co., Ltd. | Polycyclic derivatives, preparation method and medical uses thereof |
JP6130401B2 (ja) | 2012-01-20 | 2017-05-17 | アンナプラガダ,アナンス | 医学画像を客観的に特徴付けるための方法および組成物 |
AU2013290100A1 (en) | 2012-07-11 | 2015-01-29 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
GB201216018D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Pharmacologically active compounds |
US9708270B2 (en) | 2012-10-11 | 2017-07-18 | Merck Sharp & Dohme Corp. | Substituted spiropiperidinyl compounds useful as GPR120 agonists |
KR101942752B1 (ko) | 2012-11-05 | 2019-01-28 | 주식회사 엘지화학 | Gpr120 효능제로서의 티오아릴 유도체 |
TWI692469B (zh) * | 2012-11-09 | 2020-05-01 | 南韓商Lg化學股份有限公司 | Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
EP2970182B1 (en) | 2013-03-14 | 2017-05-03 | Janssen Pharmaceutica NV | Bicyclic pyrrole derivatives useful as agonists of gpr120 |
EP2970157B1 (en) | 2013-03-14 | 2018-04-25 | Janssen Pharmaceutica NV | Benzo-fused heterocyclic derivatives useful as agonists of gpr120 |
JP6336561B2 (ja) | 2013-03-14 | 2018-06-06 | ヤンセン ファーマシューティカ エヌ.ベー. | Ii型糖尿病を処置するためのgpr120アゴニスト |
CN104109115B (zh) * | 2013-04-16 | 2016-11-23 | 中国科学院上海药物研究所 | 一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途 |
JP6322704B2 (ja) | 2013-06-27 | 2018-05-09 | エルジー・ケム・リミテッド | Gpr120アゴニストとしてのビアリール誘導体 |
GB201314452D0 (en) | 2013-08-13 | 2013-09-25 | Ostara Biomedical Ltd | Embryo implantation |
CA2935897C (en) | 2014-02-19 | 2018-07-03 | Piramal Enterprises Limited | Compounds for use as gpr120 agonists |
US9067898B1 (en) | 2014-03-07 | 2015-06-30 | Janssen Pharmaceutica Nv | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes |
US8912227B1 (en) | 2014-03-07 | 2014-12-16 | Janssen Pharmaceutica Nv | Bicyclic pyrrole derivatives useful as agonists of GPR120 |
ES2673578T3 (es) * | 2014-03-07 | 2018-06-22 | Janssen Pharmaceutica Nv | Derivados de isotiazol como agonistas GPR120 para el tratamiento de diabetes de tipo II |
MX362341B (es) | 2014-05-01 | 2019-01-11 | Novartis Ag | Compuestos y composiciones como agonistas del receptor tipo toll 7. |
AU2015253225B2 (en) | 2014-05-01 | 2017-04-06 | Novartis Ag | Compounds and compositions as Toll-Like Receptor 7 agonists |
EP3172185B1 (en) | 2014-07-25 | 2020-03-04 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
CA2960757C (en) | 2014-09-11 | 2022-09-06 | Piramal Enterprises Limited | Fused heterocyclic compounds as gpr120 agonists |
AU2015330824A1 (en) | 2014-10-08 | 2017-05-25 | Ananth Annapragada | MRI imaging of amyloid plaque using liposomes |
GB201501302D0 (en) | 2015-01-27 | 2015-03-11 | Ostara Biomedical Ltd | Embryo implantation |
AU2016213929C1 (en) | 2015-02-05 | 2020-05-28 | Piramal Enterprises Limited | Compounds containing carbon-carbon linker as GPR120 agonists |
EP3932914A1 (en) | 2015-03-13 | 2022-01-05 | Valo Health, Inc. | Alpha-cinnamide compounds and compositions as hdac8 inhibitors |
GB201517523D0 (en) | 2015-10-05 | 2015-11-18 | Ostara Biomedical Ltd | Methods and compositions for managing reproduction |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN107176944B (zh) * | 2016-03-11 | 2020-05-01 | 中国科学院上海药物研究所 | 一种噻吩羧酸类化合物或其衍生物、其药物组合物、制备方法和用途 |
WO2017216727A1 (en) | 2016-06-13 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as inhibitors of dnmt1 |
WO2018049324A1 (en) | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Monocyclic compounds useful as gpr120 modulators |
JP7065081B2 (ja) | 2016-09-12 | 2022-05-11 | インテグラル ヘルス, インコーポレイテッド | Gpr120モジュレーターとして有用な二環式化合物 |
CN111285914B (zh) * | 2018-12-10 | 2023-02-17 | 江西青峰药业有限公司 | 一种奥贝胆酸的制备方法 |
CN109694332A (zh) * | 2018-12-27 | 2019-04-30 | 四川大学 | 一种苄胺衍生物烯基化的方法 |
CN110746450A (zh) * | 2019-09-17 | 2020-02-04 | 济南康和医药科技有限公司 | 一种贝前列素钠关键中间体的合成方法 |
US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
EP4175719A1 (en) | 2020-07-02 | 2023-05-10 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
CN114163426B (zh) * | 2020-09-10 | 2024-03-19 | 上海爱博医药科技有限公司 | 苯并含氧杂环类化合物及其医药应用 |
CN112608378B (zh) * | 2020-12-09 | 2023-09-08 | 江苏师范大学 | 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
WO2022182954A1 (en) * | 2021-02-26 | 2022-09-01 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for treating type 2 diabetes using granulocyte-macrophage colony-stimulating factor (gm-csf) |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US3916889A (en) * | 1973-09-28 | 1975-11-04 | Sandoz Ag | Patient ventilator apparatus |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4888353A (en) | 1986-02-28 | 1989-12-19 | Erbamont, Inc. | Carboxamides useful as antiemetic or antipsychotic agents |
US4705554A (en) * | 1985-12-03 | 1987-11-10 | Mitsubishi Chemical Industries Limited | Benzofuranyloxyphenylurea derivative and herbicidal composition containing it as an active ingredient |
US5032577A (en) | 1986-12-31 | 1991-07-16 | Abbott Laboratories | Peptidylaminodiols |
ES2051843T3 (es) * | 1987-05-11 | 1994-07-01 | Ono Pharmaceutical Co | Un proceso para la preparacion de un derivado del acido benzoilaminofenoxibutanico. |
US4959092A (en) * | 1987-06-03 | 1990-09-25 | Mitsubishi Kasei Corporation | Substituted phenyl (or pyridyl) urea compound and herbicidal composition containing the same as active ingredient |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US6514996B2 (en) * | 1995-05-19 | 2003-02-04 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of benzofuran or benzodioxole |
AU697976B2 (en) * | 1995-12-05 | 1998-10-22 | Darwin Discovery Limited | Benzofuran carboxamides and sulphonamides |
DK0923568T5 (da) * | 1996-08-19 | 2003-11-03 | Altana Pharma Ag | Hidtil ukendte benzofuran-4-carboxamider |
DE19648793A1 (de) * | 1996-11-26 | 1998-05-28 | Basf Ag | Neue Benzamide und deren Anwendung |
AU8750298A (en) * | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
KR100620337B1 (ko) | 1998-03-10 | 2006-09-13 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 |
US6262118B1 (en) | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
US6921767B2 (en) | 2000-06-15 | 2005-07-26 | Pharmacia Corporation | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives |
CA2487315A1 (en) | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
AU2003254781A1 (en) | 2002-07-31 | 2004-02-16 | Nippon Soda Co., Ltd. | Aminosalicylamide derivative, process for producing the same and agri-horticultural pesticide |
TWI343915B (en) | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
EP2385032A1 (en) | 2002-11-08 | 2011-11-09 | Takeda Pharmaceutical Company Limited | GPR40 Receptor function regulator |
CN1735408A (zh) * | 2002-11-08 | 2006-02-15 | 武田药品工业株式会社 | 受体机能调节剂 |
CA2509202A1 (en) * | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
WO2005009104A2 (en) * | 2003-07-16 | 2005-02-03 | Ligand Pharmacueticals Incorporated | Benzoic and phenyl acetic acid derivatives as hnf-4 modulators |
US7834013B2 (en) | 2003-11-19 | 2010-11-16 | Glaxosmithkline Llc | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40 |
JP4922615B2 (ja) * | 2003-11-26 | 2012-04-25 | 武田薬品工業株式会社 | 受容体機能調節剤 |
JP2007520471A (ja) * | 2003-12-22 | 2007-07-26 | イーライ リリー アンド カンパニー | Ppar受容体調節物質としての二環式誘導体 |
BRPI0507802A (pt) | 2004-02-18 | 2007-07-10 | Metabolex Inc | composto, composição, e, método para tratar inflamação ou um distúrbio metabólico |
EA011010B1 (ru) | 2004-02-27 | 2008-12-30 | Эмджен, Инк. | Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина |
WO2006057448A1 (ja) | 2004-11-26 | 2006-06-01 | Takeda Pharmaceutical Company Limited | アリールアルカン酸誘導体 |
EP2592066B1 (en) * | 2004-12-13 | 2014-12-03 | Ono Pharmaceutical Co., Ltd. | Aminocarboxylic acid derivative and medical use thereof |
JP2008538351A (ja) | 2005-03-21 | 2008-10-23 | メタボレックス インコーポレーティッド | 癌を含むPPARγ反応性疾患の処置または予防における浮腫を回避するための方法 |
US8138209B2 (en) * | 2005-07-13 | 2012-03-20 | Jenrin Discovery, Inc. | Substituted picolinamides as MAO-B inhibitors useful for treating obesity |
CA2615291A1 (en) * | 2005-07-14 | 2007-01-18 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
WO2007013689A1 (ja) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | シクロプロパンカルボン酸化合物 |
TW200800999A (en) | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
US20090203577A1 (en) * | 2005-12-15 | 2009-08-13 | Exelixis, Inc. | Azepinoindole Derivatives As Pharmaceutical Agents |
JP2009530281A (ja) * | 2006-03-14 | 2009-08-27 | アムジエン・インコーポレーテツド | 代謝障害の治療に有用である二環式カルボン酸誘導体 |
PT2248812E (pt) | 2006-06-27 | 2014-03-12 | Takeda Pharmaceutical | Compostos cíclicos fundidos como moduladores do receptor gpr40 |
WO2008030618A1 (en) * | 2006-09-07 | 2008-03-13 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
WO2008054674A2 (en) * | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
JP2010508268A (ja) | 2006-10-31 | 2010-03-18 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病二環式化合物 |
TW200838526A (en) * | 2006-12-01 | 2008-10-01 | Astellas Pharma Inc | Carboxylic acid derivatives |
KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Lxr 및 fxr 조절자 |
WO2008103500A1 (en) | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
CA2677706A1 (en) | 2007-02-22 | 2008-08-28 | Irm Llc | Compounds and methods for modulating g protein-coupled receptors |
JP2010524932A (ja) | 2007-04-16 | 2010-07-22 | アムジエン・インコーポレーテツド | 置換ビフェニルフェノキシ−、チオフェニル−及びアミノフェニルプロパン酸gpr40調節物質 |
SA08290245B1 (ar) * | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
US8318781B2 (en) * | 2007-04-26 | 2012-11-27 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
TWI446905B (zh) * | 2007-06-05 | 2014-08-01 | Sanofi Aventis | 經取代之苯甲醯基胺基-氫茚-2-羧酸及相關化合物 |
WO2009046371A1 (en) | 2007-10-05 | 2009-04-09 | Metabolex, Inc. | Methods of treating metabolic diseases |
EP2205548A1 (en) | 2007-10-10 | 2010-07-14 | Amgen, Inc | Substituted biphenyl gpr40 modulators |
JP5632612B2 (ja) * | 2007-12-05 | 2014-11-26 | あすか製薬株式会社 | ラクタム化合物又はその塩及びppar活性化剤 |
AU2009255183A1 (en) | 2008-06-02 | 2009-12-10 | Msd K.K. | Novel isoxazole derivative |
JP2012506386A (ja) | 2008-10-21 | 2012-03-15 | メタボレックス, インコーポレイテッド | アリールgpr120受容体アゴニストおよびその使用 |
AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
-
2009
- 2009-12-16 AR ARP090104925A patent/AR074760A1/es unknown
- 2009-12-17 CN CN201410242507.8A patent/CN103980235A/zh active Pending
- 2009-12-17 SG SG2014004048A patent/SG196838A1/en unknown
- 2009-12-17 ES ES09796212T patent/ES2416980T3/es active Active
- 2009-12-17 KR KR1020117016300A patent/KR20110096071A/ko not_active Application Discontinuation
- 2009-12-17 CN CN200980156131.6A patent/CN102307860B/zh not_active Expired - Fee Related
- 2009-12-17 UA UAA201108818A patent/UA105779C2/uk unknown
- 2009-12-17 WO PCT/US2009/068576 patent/WO2010080537A1/en active Application Filing
- 2009-12-17 EP EP20120174635 patent/EP2514745A1/en not_active Withdrawn
- 2009-12-17 SG SG2011043130A patent/SG172125A1/en unknown
- 2009-12-17 MX MX2011006574A patent/MX2011006574A/es active IP Right Grant
- 2009-12-17 NZ NZ611429A patent/NZ611429A/en not_active IP Right Cessation
- 2009-12-17 EA EA201190053A patent/EA021515B1/ru not_active IP Right Cessation
- 2009-12-17 EP EP09796212.0A patent/EP2367793B8/en not_active Not-in-force
- 2009-12-17 BR BRPI0922483A patent/BRPI0922483A2/pt not_active IP Right Cessation
- 2009-12-17 NZ NZ593906A patent/NZ593906A/xx not_active IP Right Cessation
- 2009-12-17 DK DK09796212.0T patent/DK2367793T3/da active
- 2009-12-17 CA CA2746762A patent/CA2746762A1/en not_active Abandoned
- 2009-12-17 US US12/641,263 patent/US8309600B2/en not_active Expired - Fee Related
- 2009-12-17 AU AU2009335797A patent/AU2009335797A1/en not_active Abandoned
- 2009-12-17 JP JP2011542451A patent/JP5746975B2/ja not_active Expired - Fee Related
- 2009-12-18 TW TW098143781A patent/TW201028389A/zh unknown
-
2011
- 2011-06-15 IL IL213569A patent/IL213569A0/en unknown
- 2011-06-17 SV SV2011003954A patent/SV2011003954A/es unknown
- 2011-06-17 EC EC2011011149A patent/ECSP11011149A/es unknown
- 2011-06-17 CL CL2011001497A patent/CL2011001497A1/es unknown
- 2011-06-17 NI NI201100126A patent/NI201100126A/es unknown
- 2011-06-17 CR CR20110344A patent/CR20110344A/es unknown
- 2011-06-20 CO CO11076781A patent/CO6400136A2/es active IP Right Grant
- 2011-06-21 ZA ZA2011/04570A patent/ZA201104570B/en unknown
-
2012
- 2012-03-06 HK HK12102249.1A patent/HK1162023A1/xx not_active IP Right Cessation
- 2012-10-05 US US13/646,409 patent/US8598374B2/en not_active Expired - Fee Related
-
2013
- 2013-10-15 US US14/054,385 patent/US20140121246A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6400136A2 (es) | Agosnistas del receptor gpr120 y usos de los mismos | |
ECSP11010989A (es) | Agonistas del receptor gpr120 de arilo y usos de los mismos | |
CY1121114T1 (el) | Αγωνιστες γλυκαγονης/glp-1 για τη θεραπεια της παχυσαρκιας | |
AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
MX2010013876A (es) | Agonistas de arilo grpr119 y sus usos . | |
CL2012000583A1 (es) | Compuestos derivados de quinazolinas sustituidas, inhibidores de los canales ionicos de potasio; composicion farmaceutica que los comprende; uso del compuesto para tratar o prevenir arritmias, controlar la frecuencia cardiaca, entre otras. | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
MX2018005132A (es) | Agonistas del receptor de glucagon. | |
CL2011000978A1 (es) | Compuestos derivados de fenil-amida o piridil-amida, agonistas de gpbar1; proceso de preparacion; composicion farmaceutica; y su uso en diabetes, isquemia, obesidad, dislipidemia, entre otras. | |
CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2010001538A1 (es) | Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular. | |
AR073563A1 (es) | Terapia de combinacion para el tratamiento de diabetes y estados relacionados | |
CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
EA201070722A1 (ru) | Пептидомиметики с активностью антагонистов глюкагона и агонистов glp-1 | |
CL2017000818A1 (es) | Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii | |
CU23853B1 (es) | Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2 | |
PA8827501A1 (es) | Pirrolidin amidas sustituidas como moduladores del receptor histamina h3 | |
CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. | |
CR20110023A (es) | Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida | |
UY32719A (es) | Agonistas del receptor gpr 120 y usos de los mismos | |
HN2011001703A (es) | Agonistas del receptor gpr 120 y usos de los mismos | |
SV2011003821A (es) | Compuestos de fenantrenona, composiciones y metodos | |
TH115438A (th) | Gpr120 รีเซปเตอร์ อะโกนิสท์ และ การใช้ของมัน | |
CL2007000741A1 (es) | Compuestos derivados heterociclicos, moduladores del receptor de s1p-1(esfingosina-1-fosfato); y uso para tratar rechazo de transplante, cancer, enfermedades autoinmunes,inflamatorias, artritis reumatoide, diabetes mellitus tipo i y ii, psoriasis, entre otras. | |
DOP2009000063A (es) | Compuestos antagonistas del receptor de glucagon, composiciones que contiene dichos compuestos y procedimientos |